CXCR4 and neoplasm: Moreover, we have also developed a CXCR4+ subcutaneous (SC) model which we next used to demonstrate that the protein-based T22-GFP-H6 nanocarrier that targets CXCR4+ cells, displays a high selectivity in its accumulation in CXCR4+ EC tumor tissues.